logo
Plus   Neg
Share
Email

J&J, U.S. Expand Agreement To Support Next Phase Of COVID-19 Vaccine R&D

Johnson & Johnson (JNJ) said Saturday that the company and the U.S. Department of Health & Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development.

As per the agreement, the company's Janssen will commit about $604 million and the U.S. Department of Health & Human Services' the Biomedical Advanced Research and Development Authority or BARDA will commit about $454 million to support the ongoing Phase 3 ENSEMBLE trial.

The trial is evaluating Janssen's investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J&J Distributing has recalled various food products citing potential contamination with Listeria monocytogenes or Lm, an organism that can cause serious and sometimes fatal infections. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, around 33 pounds of ready-to-eat meat and poultry salads and wrap products have been called back. The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate.
Follow RTT